EUVIMEDEUVIMED entdecken
Crossref

PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide

Kadeer Tudi, Zhisheng Jie, Zihao Chen, Weijiang Liao, Yi Liu, Ganghua Tang iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5620-5629

DOI: 10.1021/acs.molpharmaceut.6c00761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.10.2026. Verfasst von Kadeer Tudi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Eva…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor, Positron-Emission Tomography, Fluorine Radioisotopes, Radiopharmaceuticals. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Department of Education of Guangdong Province, Southern Medical University, Medical Products Administration of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide is a clinical dual GLP-1R and GIPR agonist for type 2 diabetes and obesity, and non-invasive approaches to assess its in vivo biodistribution and systemic toxicity in living animals remain limited. Both receptors also serve as potential targets for neuroendocrine tumor imaging, and dual-target PET probes for simultaneous GLP-1R and GIPR detection are still lacking. Herein, we developed a novel PET probe [18F]AlF-NOTA-Asp2-tirzepatide via structural modification of tirzepatide. This probe successfully visualized the in vivo distribution of tirzepatide, which was primarily eliminated through the renal system. The C20 fatty diacid moiety caused elevated uptake in the heart, liver and blood due to enhanced albumin binding. In vitro assays verified its reliable GLP-1R and moderate GIPR binding affinity. Persistent tumor accumulation was observed in INS-1 and A549-GIPR xenografts, allowing effective tumor visualization. In summary, [18F]AlF-NOTA-Asp2-tirzepatide features facile radiolabeling and enables the clear visualization of tirzepatide in vivo, along with favorable dual-targeting performance, while excessive non-target uptake still needs to be optimized for further clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorPositron-Emission TomographyFluorine RadioisotopesRadiopharmaceuticalsAnimalsTirzepatideHumansMiceTissue DistributionCell Line, TumorMice, NudeHeterocyclic Compounds, 1-RingHeterocyclic CompoundsFemale

Stichwörter der Autor:innen

GIPRGLP-1RPET imaging[18F]fluoridetirzepatide

Substanzen

TirzepatideGlucagon-Like Peptide-1 ReceptorFluorine RadioisotopesRadiopharmaceuticalsHeterocyclic Compounds, 1-Ring1,4,7-triazacyclononane-N,N',N''-triacetic acidGLP1R protein, humanHeterocyclic Compounds

Autor:innen und Institutionen

  • Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfa…
  • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong Province 510515, China.

ORCID-Profile: Ganghua Tang

Förderung

  • Department of Education of Guangdong Province
  • Southern Medical University
  • Medical Products Administration of Guangdong Province

Zitieren

APA

Tudi, K., Jie, Z., Chen, Z., Liao, W., Liu, Y., & Tang, G. (2026). PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide. Molecular Pharmaceutics, 23(11), 5620-5629. https://doi.org/10.1021/acs.molpharmaceut.6c00761

Vancouver

Tudi K, Jie Z, Chen Z, Liao W, Liu Y, Tang G. PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide. Molecular Pharmaceutics. 2026;23(11):5620-5629. doi:10.1021/acs.molpharmaceut.6c00761

BibTeX
@article{Tudi2026,
  author = {Tudi, Kadeer and Jie, Zhisheng and Chen, Zihao and Liao, Weijiang and Liu, Yi and Tang, Ganghua},
  title = {PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5620--5629},
  doi = {10.1021/acs.molpharmaceut.6c00761}
}
Kostenlos starten →